Wnt signaling in Alzheimer's disease: Up or down, that is the question

Ageing Research Reviews

Volumn 8, Issue 2, 2009, Pages 71-82

  Boonen, Rick A C M ^a   van Tijn, Paula ^a   Zivkovic, Danica ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Catenin; Alzheimer's disease; GSK 3; Lithium; Presenilin; Wnt signaling

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; BETA CATENIN; LITHIUM; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; MEVINOLIN; TAU PROTEIN; VALPROIC ACID; WNT PROTEIN;

ALZHEIMER DISEASE; CELL CYCLE; CYTOPLASM; DOWN REGULATION; DRUG INHIBITION; DRUG TARGETING; HUMAN; NERVE CELL DEGENERATION; NERVE CELL PLASTICITY; NEUROFIBRILLARY TANGLE; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; SHORT SURVEY; SIGNAL TRANSDUCTION; UPREGULATION;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BETA CATENIN; DOWN-REGULATION; GLYCOGEN SYNTHASE KINASE 3; HUMANS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TAU PROTEINS; UP-REGULATION; WNT PROTEINS;

EID: 60949111784     PISSN: 15681637     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arr.2008.11.003     Document Type: Short Survey

References (133)

1. Alvarez A.R., Godoy J.A., Mullendorff K., Olivares G.H., Bronfman M., and Inestrosa N.C. Wnt-3a overcomes beta-amyloid toxicity in rat hippocampal neurons. Exp. Cell Res. 297 1 (2004) 186-196
2. Amit S., Hatzubai A., Birman Y., Andersen J.S., Ben-Shushan E., Mann M., Ben-Neriah Y., and Alkalay I. Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway. Genes Dev. 16 9 (2002) 1066-1076
3. Annaert W.G., Levesque L., Craessaerts K., Dierinck I., Snellings G., Westaway D., George-Hyslop P.S., Cordell B., Fraser P., and De Strooper B. Presenilin 1 controls gamma-secretase processing of amyloid precursor protein in pre-golgi compartments of hippocampal neurons. J. Cell Biol. 147 2 (1999) 277-294
4. Asuni A.A., Hooper C., Reynolds C.H., Lovestone S., Anderton B.H., and Killick R. GSK3alpha exhibits beta-catenin and tau directed kinase activities that are modulated by Wnt. Eur. J. Neurosci. 24 12 (2006) 3387-3392
5. Baki L., Neve R.L., Shao Z., Shioi J., Georgakopoulos A., and Robakis N.K. Wild-type but not FAD mutant presenilin-1 prevents neuronal degeneration by promoting phosphatidylinositol 3-kinase neuroprotective signaling. J. Neurosci. 28 2 (2008) 483-490
6. Baki L., Shioi J., Wen P., Shao Z., Schwarzman A., Gama-Sosa M., Neve R., and Robakis N.K. PS1 activates PI3K thus inhibiting GSK-3 activity and tau overphosphorylation: effects of FAD mutations. EMBO J. 23 13 (2004) 2586-2596
7. Ballatore C., Lee V.M., and Trojanowski J.Q. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat. Rev. Neurosci. 8 9 (2007) 663-672
8. Beaulieu J.M., Marion S., Rodriguiz R.M., Medvedev I.O., Sotnikova T.D., Ghisi V., Wetsel W.C., Lefkowitz R.J., Gainetdinov R.R., and Caron M.G. A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell 132 1 (2008) 125-136
9. Bentahir M., Nyabi O., Verhamme J., Tolia A., Horre K., Wiltfang J., Esselmann H., and De Strooper B. Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J. Neurochem. 96 3 (2006) 732-742
10. Berezovska O., Xia M.Q., and Hyman B.T. Notch is expressed in adult brain, is coexpressed with presenilin-1, and is altered in Alzheimer disease. J. Neuropathol. Exp. Neurol. 57 8 (1998) 738-745
11. Blalock E.M., Geddes J.W., Chen K.C., Porter N.M., Markesbery W.R., and Landfield P.W. Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc. Natl. Acad. Sci. U.S.A. 101 7 (2004) 2173-2178
12. Brunner E., Peter O., Schweizer L., and Basler K. pangolin encodes a Lef-1 homologue that acts downstream of Armadillo to transduce the Wingless signal in Drosophila. Nature 385 6619 (1997) 829-833
13. Caccamo A., Oddo S., Tran L.X., and LaFerla F.M. Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. Am. J. Pathol. 170 5 (2007) 1669-1675
14. Caricasole A., Copani A., Caraci F., Aronica E., Rozemuller A.J., Caruso A., Storto M., Gaviraghi G., Terstappen G.C., and Nicoletti F. Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain. J. Neurosci. 24 26 (2004) 6021-6027
15. Caricasole A., Copani A., Caruso A., Caraci F., Iacovelli L., Sortino M.A., Terstappen G.C., and Nicoletti F. The Wnt pathway, cell-cycle activation and beta-amyloid: novel therapeutic strategies in Alzheimer's disease?. Trends Pharmacol. Sci. 24 5 (2003) 233-238
16. Caruso A., Motolese M., Iacovelli L., Caraci F., Copani A., Nicoletti F., Terstappen G.C., Gaviraghi G., and Caricasole A. Inhibition of the canonical Wnt signaling pathway by apolipoprotein E4 in PC12 cells. J. Neurochem. 98 2 (2006) 364-371
17. Cavallo R.A., Cox R.T., Moline M.M., Roose J., Polevoy G.A., Clevers H., Peifer M., and Bejsovec A. Drosophila Tcf and Groucho interact to repress Wingless signalling activity. Nature 395 6702 (1998) 604-608
18. Cedazo-Minguez A. Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities. J. Cell. Mol. Med. 11 6 (2007) 1227-1238
19. Chen G., Zeng W.Z., Yuan P.X., Huang L.D., Jiang Y.M., Zhao Z.H., and Manji H.K. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J. Neurochem. 72 2 (1999) 879-882
20. Chen R.W., and Chuang D.M. Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. J. Biol. Chem. 274 10 (1999) 6039-6042
21. Chevallier N.L., Soriano S., Kang D.E., Masliah E., Hu G., and Koo E.H. Perturbed neurogenesis in the adult hippocampus associated with presenilin-1 A246E mutation. Am. J. Pathol. 167 1 (2005) 151-159
22. Ciani L., and Salinas P.C. WNTs in the vertebrate nervous system: from patterning to neuronal connectivity. Nat. Rev. Neurosci. 6 5 (2005) 351-362
23. Claycomb J.M., Benasutti M., Bosco G., Fenger D.D., and Orr-Weaver T.L. Gene amplification as a developmental strategy: isolation of two developmental amplicons in Drosophila. Dev. Cell 6 1 (2004) 145-155
24. Cole A.R., Astell A., Green C., and Sutherland C. Molecular connexions between dementia and diabetes. Neurosci. Biobehav. Rev. 31 7 (2007) 1046-1063
25. Copani A., Hoozemans J.J., Caraci F., Calafiore M., Van Haastert E.S., Veerhuis R., Rozemuller A.J., Aronica E., Sortino M.A., and Nicoletti F. DNA polymerase-beta is expressed early in neurons of Alzheimer's disease brain and is loaded into DNA replication forks in neurons challenged with beta-amyloid. J. Neurosci. 26 43 (2006) 10949-10957
26. Copani A., Sortino M.A., Caricasole A., Chiechio S., Chisari M., Battaglia G., Giuffrida-Stella A.M., Vancheri C., and Nicoletti F. Erratic expression of DNA polymerases by beta-amyloid causes neuronal death. FASEB J. 16 14 (2002) 2006-2008
27. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., and Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261 5123 (1993) 921-923
28. Culmsee C., and Mattson M.P. p53 in neuronal apoptosis. Biochem. Biophys. Res. Commun. 331 3 (2005) 761-777
29. Davidson G., Wu W., Shen J., Bilic J., Fenger U., Stannek P., Glinka A., and Niehrs C. Casein kinase 1 gamma couples Wnt receptor activation to cytoplasmic signal transduction. Nature 438 7069 (2005) 867-872
30. De Ferrari G.V., and Moon R.T. The ups and downs of Wnt signaling in prevalent neurological disorders. Oncogene 25 57 (2006) 7545-7553
31. De Ferrari G.V., Papassotiropoulos A., Biechele T., Wavrant De-Vrieze F., Avila M.E., Major M.B., Myers A., Saez K., Henriquez J.P., Zhao A., Wollmer M.A., Nitsch R.M., Hock C., Morris C.M., Hardy J., and Moon R.T. Common genetic variation within the low-density lipoprotein receptor-related protein 6 and late-onset Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 104 22 (2007) 9434-9439
32. De Strooper B., Annaert W., Cupers P., Saftig P., Craessaerts K., Mumm J.S., Schroeter E.H., Schrijvers V., Wolfe M.S., Ray W.J., Goate A., and Kopan R. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 398 6727 (1999) 518-522
33. Doble B.W., Patel S., Wood G.A., Kockeritz L.K., and Woodgett J.R. Functional redundancy of GSK-3alpha and GSK-3beta in Wnt/beta-catenin signaling shown by using an allelic series of embryonic stem cell lines. Dev. Cell 12 6 (2007) 957-971
34. Farias G.G., Godoy J.A., Vazquez M.C., Adani R., Meshulam H., Avila J., Amitai G., and Inestrosa N.C. The anti-inflammatory and cholinesterase inhibitor bifunctional compound IBU-PO protects from beta-amyloid neurotoxicity by acting on Wnt signaling components. Neurobiol. Dis. 18 1 (2005) 176-183
35. Gatz M., Reynolds C.A., Fratiglioni L., Johansson B., Mortimer J.A., Berg S., Fiske A., and Pedersen N.L. Role of genes and environments for explaining Alzheimer disease. Arch. Gen. Psychiatry 63 2 (2006) 168-174
36. Geschwind D.H. Tau phosphorylation, tangles, and neurodegeneration: the chicken or the egg?. Neuron 40 3 (2003) 457-460
37. Ghanevati M., and Miller C.A. Phospho-beta-catenin accumulation in Alzheimer's disease and in aggresomes attributable to proteasome dysfunction. J. Mol. Neurosci. 25 1 (2005) 79-94
38. Gibson G.E., and Huang H.M. Oxidative stress in Alzheimer's disease. Neurobiol. Aging 26 5 (2005) 575-578
39. Gonzalez-Sancho J.M., Aguilera O., Garcia J.M., Pendas-Franco N., Pena C., Cal S., Garcia de Herreros A., Bonilla F., and Munoz A. The Wnt antagonist DICKKOPF-1 gene is a downstream target of beta-catenin/TCF and is downregulated in human colon cancer. Oncogene 24 6 (2005) 1098-1103
40. Gordon M.D., and Nusse R. Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J. Biol. Chem. 281 32 (2006) 22429-22433
41. Guger K.A., and Gumbiner B.M. A mode of regulation of beta-catenin signaling activity in Xenopus embryos independent of its levels. Dev. Biol. 223 2 (2000) 441-448
42. Haass C., and Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 8 2 (2007) 101-112
43. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 5580 (2002) 353-356
44. Hayward P., Brennan K., Sanders P., Balayo T., DasGupta R., Perrimon N., and Martinez Arias A. Notch modulates Wnt signalling by associating with Armadillo/beta-catenin and regulating its transcriptional activity. Development 132 8 (2005) 1819-1830
45. Heinitz K., Beck M., Schliebs R., and Perez-Polo J.R. Toxicity mediated by soluble oligomers of beta-amyloid(1-42) on cholinergic SN56.B5.G4 cells. J. Neurochem. 98 6 (2006) 1930-1945
46. Herrup K., Neve R., Ackerman S.L., and Copani A. Divide and die: cell cycle events as triggers of nerve cell death. J. Neurosci. 24 42 (2004) 9232-9239
47. Holtzman D.M., Bales K.R., Tenkova T., Fagan A.M., Parsadanian M., Sartorius L.J., Mackey B., Olney J., McKeel D., Wozniak D., and Paul S.M. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 97 6 (2000) 2892-2897
48. Hong M., Chen D.C., Klein P.S., and Lee V.M. Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J. Biol. Chem. 272 40 (1997) 25326-25332
49. Hooper C., Killick R., and Lovestone S. The GSK3 hypothesis of Alzheimer's disease. J. Neurochem. 104 6 (2008) 1433-1439
50. Hsia A.Y., Masliah E., McConlogue L., Yu G.Q., Tatsuno G., Hu K., Kholodenko D., Malenka R.C., Nicoll R.A., and Mucke L. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl. Acad. Sci. U.S.A. 96 6 (1999) 3228-3233
51. Iqbal K., and Grundke-Iqbal I. Alzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention. J. Cell. Mol. Med. 12 1 (2008) 38-55
52. Jackson G.R., Wiedau-Pazos M., Sang T.K., Wagle N., Brown C.A., Massachi S., and Geschwind D.H. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron 34 4 (2002) 509-519
53. Jiang H., Guo W., Liang X., and Rao Y. Both the establishment and the maintenance of neuronal polarity require active mechanisms: critical roles of GSK-3beta and its upstream regulators. Cell 120 1 (2005) 123-135
54. Kaether C., Lammich S., Edbauer D., Ertl M., Rietdorf J., Capell A., Steiner H., and Haass C. Presenilin-1 affects trafficking and processing of betaAPP and is targeted in a complex with nicastrin to the plasma membrane. J. Cell Biol. 158 3 (2002) 551-561
55. Kang D.E., Pietrzik C.U., Baum L., Chevallier N., Merriam D.E., Kounnas M.Z., Wagner S.L., Troncoso J.C., Kawas C.H., Katzman R., and Koo E.H. Modulation of amyloid beta-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway. J. Clin. Invest. 106 9 (2000) 1159-1166
56. Kang D.E., Soriano S., Frosch M.P., Collins T., Naruse S., Sisodia S.S., Leibowitz G., Levine F., and Koo E.H. Presenilin 1 facilitates the constitutive turnover of beta-catenin: differential activity of Alzheimer's disease-linked PS1 mutants in the beta-catenin-signaling pathway. J. Neurosci. 19 11 (1999) 4229-4237
57. Kang D.E., Soriano S., Xia X., Eberhart C.G., De Strooper B., Zheng H., and Koo E.H. Presenilin couples the paired phosphorylation of beta-catenin independent of axin: implications for beta-catenin activation in tumorigenesis. Cell 110 6 (2002) 751-762
58. Kawamura Y., Kikuchi A., Takada R., Takada S., Sudoh S., Shibamoto S., Yanagisawa K., and Komano H. Inhibitory effect of a presenilin 1 mutation on the Wnt signalling pathway by enhancement of beta-catenin phosphorylation. Eur. J. Biochem. 268 10 (2001) 3036-3041
59. Kimelman D., and Xu W. beta-catenin destruction complex: insights and questions from a structural perspective. Oncogene 25 57 (2006) 7482-7491
60. Koh S.H., Noh M.Y., and Kim S.H. Amyloid-beta-induced neurotoxicity is reduced by inhibition of glycogen synthase kinase-3. Brain Res. 1188 (2008) 254-262
61. Kozlovsky N., Belmaker R.H., and Agam G. GSK-3 and the neurodevelopmental hypothesis of schizophrenia. Eur. Neuropsychopharmacol. 12 1 (2002) 13-25
62. Krupnik V.E., Sharp J.D., Jiang C., Robison K., Chickering T.W., Amaravadi L., Brown D.E., Guyot D., Mays G., Leiby K., Chang B., Duong T., Goodearl A.D., Gearing D.P., Sokol S.Y., and McCarthy S.A. Functional and structural diversity of the human Dickkopf gene family. Gene 238 2 (1999) 301-313
63. Krylova O., Messenger M.J., and Salinas P.C. Dishevelled-1 regulates microtubule stability: a new function mediated by glycogen synthase kinase-3beta. J. Cell Biol. 151 1 (2000) 83-94
64. Kumar-Singh S., De Jonghe C., Cruts M., Kleinert R., Wang R., Mercken M., De Strooper B., Vanderstichele H., Lofgren A., Vanderhoeven I., Backhovens H., Vanmechelen E., Kroisel P.M., and Van Broeckhoven C. Nonfibrillar diffuse amyloid deposition due to a gamma(42)-secretase site mutation points to an essential role for N-truncated A beta(42) in Alzheimer's disease. Human Mol. Genet. 9 18 (2000) 2589-2598
65. Kumar-Singh S., Theuns J., Van Broeck B., Pirici D., Vennekens K., Corsmit E., Cruts M., Dermaut B., Wang R., and Van Broeckhoven C. Mean age-of-onset of familial Alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40. Human Mutat. 27 7 (2006) 686-695
66. LaFerla F.M., Green K.N., and Oddo S. Intracellular amyloid-beta in Alzheimer's disease. Nat. Rev. Neurosci. 8 7 (2007) 499-509
67. Lein E.S., Hawrylycz M.J., Ao N., Ayres M., Bensinger A., Bernard A., Boe A.F., Boguski M.S., Brockway K.S., Byrnes E.J., Chen L., Chen L., Chen T.M., Chin M.C., Chong J., Crook B.E., Czaplinska A., Dang C.N., Datta S., Dee N.R., Desaki A.L., Desta T., Diep E., Dolbeare T.A., Donelan M.J., Dong H.W., Dougherty J.G., Duncan B.J., Ebbert A.J., Eichele G., Estin L.K., Faber C., Facer B.A., Fields R., Fischer S.R., Fliss T.P., Frensley C., Gates S.N., Glattfelder K.J., Halverson K.R., Hart M.R., Hohmann J.G., Howell M.P., Jeung D.P., Johnson R.A., Karr P.T., Kawal R., Kidney J.M., Knapik R.H., Kuan C.L., Lake J.H., Laramee A.R., Larsen K.D., Lau C., Lemon T.A., Liang A.J., Liu Y., Luong L.T., Michaels J., Morgan J.J., Morgan R.J., Mortrud M.T., Mosqueda N.F., Ng L.L., Ng R., Orta G.J., Overly C.C., Pak T.H., Parry S.E., Pathak S.D., Pearson O.C., Puchalski R.B., Riley Z.L., Rockett H.R., Rowland S.A., Royall J.J., Ruiz M.J., Sarno N.R., Schaffnit K., Shapovalova N.V., Sivisay T., Slaughterbeck C.R., Smith S.C., Smith K.A., Smith B.I., Sodt A.J., Stewart N.N., Stumpf K.R., Sunkin S.M., Sutram M., Tam A., Teemer C.D., Thaller C., Thompson C.L., Varnam L.R., Visel A., Whitlock R.M., Wohnoutka P.E., Wolkey C.K., Wong V.Y., Wood M., Yaylaoglu M.B., Young R.C., Youngstrom B.L., Yuan X.F., Zhang B., Zwingman T.A., and Jones A.R. Genome-wide atlas of gene expression in the adult mouse brain. Nature 445 7124 (2007) 168-176
68. Li H.L., Wang H.H., Liu S.J., Deng Y.Q., Zhang Y.J., Tian Q., Wang X.C., Chen X.Q., Yang Y., Zhang J.Y., Wang Q., Xu H., Liao F.F., and Wang J.Z. Phosphorylation of tau antagonizes apoptosis by stabilizing beta-catenin, a mechanism involved in Alzheimer's neurodegeneration. Proc. Natl. Acad. Sci. U.S.A. 104 9 (2007) 3591-3596
69. Liu C., Li Y., Semenov M., Han C., Baeg G.H., Tan Y., Zhang Z., Lin X., and He X. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 108 6 (2002) 837-847
70. Logan C.Y., and Nusse R. The Wnt signaling pathway in development and disease. Annu. Rev. Cell Dev. Biol. 20 (2004) 781-810
71. Lovestone S., Reynolds C.H., Latimer D., Davis D.R., Anderton B.H., Gallo J.M., Hanger D., Mulot S., Marquardt B., Stabel S., et al. Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr. Biol. 4 12 (1994) 1077-1086
72. Lucas J.J., Hernandez F., Gomez-Ramos P., Moran M.A., Hen R., and Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 20 1-2 (2001) 27-39
73. Lue L.F., Kuo Y.M., Roher A.E., Brachova L., Shen Y., Sue L., Beach T., Kurth J.H., Rydel R.E., and Rogers J. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155 3 (1999) 853-862
74. Magdesian M.H., Carvalho M.M., Mendes F.A., Saraiva L.M., Juliano M.A., Juliano L., Garcia-Abreu J., and Ferreira S.T. Amyloid-beta binds to the extracellular cysteine-rich domain of Frizzled and inhibits Wnt/beta-catenin signaling. J. Biol. Chem. 283 14 (2008) 9359-9368
75. Malik B., Currais A., Andres A., Towlson C., Pitsi D., Nunes A., Niblock M., Cooper J., Hortobagyi T., and Soriano S. Loss of neuronal cell cycle control as a mechanism of neurodegeneration in the presenilin-1 Alzheimer's disease brain. Cell Cycle 7 5 (2008) 637-646
76. Malik B., Currais A., and Soriano S. Cell cycle-driven neuronal apoptosis specifically linked to amyloid peptide Abeta1-42 exposure is not exacerbated in a mouse model of presenilin-1 familial Alzheimer's disease. J. Neurochem. 106 2 (2008) 912-916
77. Mao B., Wu W., Davidson G., Marhold J., Li M., Mechler B.M., Delius H., Hoppe D., Stannek P., Walter C., Glinka A., and Niehrs C. Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signaling. Nature 417 6889 (2002) 664-667
78. Mao B., Wu W., Li Y., Hoppe D., Stannek P., Glinka A., and Niehrs C. LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature 411 6835 (2001) 321-325
79. Mateo I., Infante J., Llorca J., Rodriguez E., Berciano J., and Combarros O. Association between glycogen synthase kinase-3beta genetic polymorphism and late-onset Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 21 4 (2006) 228-232
80. McLean C.A., Cherny R.A., Fraser F.W., Fuller S.J., Smith M.J., Beyreuther K., Bush A.I., and Masters C.L. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46 6 (1999) 860-866
81. Molenaar M., van de Wetering M., Oosterwegel M., Peterson-Maduro J., Godsave S., Korinek V., Roose J., Destree O., and Clevers H. XTcf-3 transcription factor mediates beta-catenin-induced axis formation in Xenopus embryos. Cell 86 3 (1996) 391-399
82. Munoz-Montano J.R., Moreno F.J., Avila J., and Diaz-Nido J. Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons. FEBS Lett. 411 2-3 (1997) 183-188
83. Murayama M., Tanaka S., Palacino J., Murayama O., Honda T., Sun X., Yasutake K., Nihonmatsu N., Wolozin B., and Takashima A. Direct association of presenilin-1 with beta-catenin. FEBS Lett. 433 1-2 (1998) 73-77
84. Nagy Z., Esiri M.M., Jobst K.A., Morris J.H., King E.M., McDonald B., Litchfield S., Smith A., Barnetson L., and Smith A.D. Relative roles of plaques and tangles in the dementia of Alzheimer's disease: correlations using three sets of neuropathological criteria. Dementia 6 1 (1995) 21-31
85. Naslund J., Haroutunian V., Mohs R., Davis K.L., Davies P., Greengard P., and Buxbaum J.D. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283 12 (2000) 1571-1577
86. Nishimura M., Yu G., Levesque G., Zhang D.M., Ruel L., Chen F., Milman P., Holmes E., Liang Y., Kawarai T., Jo E., Supala A., Rogaeva E., Xu D.M., Janus C., Levesque L., Bi Q., Duthie M., Rozmahel R., Mattila K., Lannfelt L., Westaway D., Mount H.T., Woodgett J., St George-Hyslop P., et al. Presenilin mutations associated with Alzheimer disease cause defective intracellular trafficking of beta-catenin, a component of the presenilin protein complex. Nat. Med. 5 2 (1999) 164-169
87. Noble W., Planel E., Zehr C., Olm V., Meyerson J., Suleman F., Gaynor K., Wang L., LaFrancois J., Feinstein B., Burns M., Krishnamurthy P., Wen Y., Bhat R., Lewis J., Dickson D., and Duff K. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc. Natl. Acad. Sci. U.S.A. 102 19 (2005) 6990-6995
88. Phiel C.J., Wilson C.A., Lee V.M., and Klein P.S. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 423 6938 (2003) 435-439
89. Poirier J. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurosci. 17 12 (1994) 525-530
90. Poirier J., Davignon J., Bouthillier D., Kogan S., Bertrand P., and Gauthier S. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 342 8873 (1993) 697-699
91. Ray W.J., Yao M., Mumm J., Schroeter E.H., Saftig P., Wolfe M., Selkoe D.J., Kopan R., and Goate A.M. Cell surface presenilin-1 participates in the gamma-secretase-like proteolysis of Notch. J. Biol. Chem. 274 51 (1999) 36801-36807
92. Rebeck G.W., Reiter J.S., Strickland D.K., and Hyman B.T. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 11 4 (1993) 575-580
93. Reddy P.H., and Beal M.F. Are mitochondria critical in the pathogenesis of Alzheimer's disease?. Brain Res. Brain Res. Rev. 49 3 (2005) 618-632
94. Rockenstein E., Torrance M., Adame A., Mante M., Bar-on P., Rose J.B., Crews L., and Masliah E. Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. J. Neurosci. 27 8 (2007) 1981-1991
95. Salins P., Shawesh S., He Y., Dibrov A., Kashour T., Arthur G., and Amara F. Lovastatin protects human neurons against Abeta-induced toxicity and causes activation of beta-catenin-TCF/LEF signaling. Neurosci. Lett. 412 3 (2007) 211-216
96. Scali C., Caraci F., Gianfriddo M., Diodato E., Roncarati R., Pollio G., Gaviraghi G., Copani A., Nicoletti F., Terstappen G.C., and Caricasole A. Inhibition of Wnt signaling, modulation of Tau phosphorylation and induction of neuronal cell death by DKK1. Neurobiol. Dis. 24 2 (2006) 254-265
97. Schmechel D.E., Saunders A.M., Strittmatter W.J., Crain B.J., Hulette C.M., Joo S.H., Pericak-Vance M.A., Goldgaber D., and Roses A.D. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 90 20 (1993) 9649-9653
98. Selenica M.L., Jensen H.S., Larsen A.K., Pedersen M.L., Helboe L., Leist M., and Lotharius J. Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation. Br. J. Pharmacol. 152 6 (2007) 959-979
99. Selkoe D., and Kopan R. Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration. Annu. Rev. Neurosci. 26 (2003) 565-597
100. Shen J., and Kelleher III R.J. The presenilin hypothesis of Alzheimer's disease: evidence for a loss-of-function pathogenic mechanism. Proc. Natl. Acad. Sci. U.S.A. 104 2 (2007) 403-409
101. Shi S.H., Cheng T., Jan L.Y., and Jan Y.N. APC and GSK-3beta are involved in mPar3 targeting to the nascent axon and establishment of neuronal polarity. Curr. Biol. 14 22 (2004) 2025-2032
102. Soriano S., Kang D.E., Fu M., Pestell R., Chevallier N., Zheng H., and Koo E.H. Presenilin 1 negatively regulates beta-catenin/T cell factor/lymphoid enhancer factor-1 signaling independently of beta-amyloid precursor protein and notch processing. J. Cell Biol. 152 4 (2001) 785-794
103. Speese S.D., and Budnik V. Wnts: up-and-coming at the synapse. Trends Neurosci. 30 6 (2007) 268-275
104. Staal F.J., Noort Mv M., Strous G.J., and Clevers H.C. Wnt signals are transmitted through N-terminally dephosphorylated beta-catenin. EMBO Rep. 3 1 (2002) 63-68
105. Stahl B., Diehlmann A., and Sudhof T.C. Direct interaction of Alzheimer's disease-related presenilin 1 with armadillo protein p0071. J. Biol. Chem. 274 14 (1999) 9141-9148
106. Strittmatter W.J., Saunders A.M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G.S., and Roses A.D. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 90 5 (1993) 1977-1981
107. Su Y., Ryder J., Li B., Wu X., Fox N., Solenberg P., Brune K., Paul S., Zhou Y., Liu F., and Ni B. Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing. Biochemistry 43 22 (2004) 6899-6908
108. Teo J.L., Ma H., Nguyen C., Lam C., and Kahn M. Specific inhibition of CBP/beta-catenin interaction rescues defects in neuronal differentiation caused by a presenilin-1 mutation. Proc. Natl. Acad. Sci. U.S.A. 102 34 (2005) 12171-12176
109. Tolwinski N.S., Wehrli M., Rives A., Erdeniz N., DiNardo S., and Wieschaus E. Wg/Wnt signal can be transmitted through arrow/LRP5,6 and Axin independently of Zw3/Gsk3beta activity. Dev. Cell 4 3 (2003) 407-418
110. Topol L., Jiang X., Choi H., Garrett-Beal L., Carolan P.J., and Yang Y. Wnt-5a inhibits the canonical Wnt pathway by promoting GSK-3-independent beta-catenin degradation. J. Cell Biol. 162 5 (2003) 899-908
111. Turenne G.A., and Price B.D. Glycogen synthase kinase3 beta phosphorylates serine 33 of p53 and activates p53's transcriptional activity. BMC Cell Biol. 2 (2001) 12
112. van de Wetering M., Cavallo R., Dooijes D., van Beest M., van Es J., Loureiro J., Ypma A., Hursh D., Jones T., Bejsovec A., Peifer M., Mortin M., and Clevers H. Armadillo coactivates transcription driven by the product of the Drosophila segment polarity gene dTCF. Cell 88 6 (1997) 789-799
113. van Tijn P., Hol E.M., van Leeuwen F.W., and Fischer D.F. The neuronal ubiquitin-proteasome system: murine models and their neurological phenotype. Prog. Neurobiol. 85 2 (2008) 176-193
114. Walsh S., and Aisen P.S. Inflammatory processes and Alzheimer's disease. Exp. Rev. Neurother. 4 5 (2004) 793-798
115. Walter J., Capell A., Grunberg J., Pesold B., Schindzielorz A., Prior R., Podlisny M.B., Fraser P., Hyslop P.S., Selkoe D.J., and Haass C. The Alzheimer's disease-associated presenilins are differentially phosphorylated proteins located predominantly within the endoplasmic reticulum. Mol. Med. 2 6 (1996) 673-691
116. Wang J., Shou J., and Chen X. Dickkopf-1, an inhibitor of the Wnt signaling pathway, is induced by p53. Oncogene 19 14 (2000) 1843-1848
117. Webber K.M., Raina A.K., Marlatt M.W., Zhu X., Prat M.I., Morelli L., Casadesus G., Perry G., and Smith M.A. The cell cycle in Alzheimer disease: a unique target for neuropharmacology. Mech. Ageing Dev. 126 10 (2005) 1019-1025
118. Westfall T.A., Brimeyer R., Twedt J., Gladon J., Olberding A., Furutani-Seiki M., and Slusarski D.C. Wnt-5/pipetail functions in vertebrate axis formation as a negative regulator of Wnt/beta-catenin activity. J. Cell Biol. 162 5 (2003) 889-898
119. Xia X., Qian S., Soriano S., Wu Y., Fletcher A.M., Wang X.J., Koo E.H., Wu X., and Zheng H. Loss of presenilin 1 is associated with enhanced beta-catenin signaling and skin tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. 98 19 (2001) 10863-10868
120. Xu W., Qiu C., Winblad B., and Fratiglioni L. The effect of borderline diabetes on the risk of dementia and Alzheimer's disease. Diabetes 56 1 (2007) 211-216
121. Xu W.L., Qiu C.X., Wahlin A., Winblad B., and Fratiglioni L. Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology 63 7 (2004) 1181-1186
122. Yang G., Zhang G., Pittelkow M.R., Ramoni M., and Tsao H. Expression profiling of UVB response in melanocytes identifies a set of p53-target genes. J. Invest. Dermatol. 126 11 (2006) 2490-2506
123. Yang T., Knowles J.K., Lu Q., Zhang H., Arancio O., Moore L.A., Chang T., Wang Q., Andreasson K., Rajadas J., Fuller G.G., Xie Y., Massa S.M., and Longo F.M. Small molecule, non-peptide p75 ligands inhibit Abeta-induced neurodegeneration and synaptic impairment. PLoS ONE 3 11 (2008) e3604
124. Yang Y., Geldmacher D.S., and Herrup K. DNA replication precedes neuronal cell death in Alzheimer's disease. J. Neurosci. 21 8 (2001) 2661-2668
125. Yang Y., and Herrup K. Cell division in the CNS: protective response or lethal event in post-mitotic neurons?. Biochim. Biophys. Acta 1772 4 (2007) 457-466
126. Yang Y., Mufson E.J., and Herrup K. Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer's disease. J. Neurosci. 23 7 (2003) 2557-2563
127. Yang Y., Varvel N.H., Lamb B.T., and Herrup K. Ectopic cell cycle events link human Alzheimer's disease and amyloid precursor protein transgenic mouse models. J. Neurosci. 26 3 (2006) 775-784
128. Yoshimura T., Kawano Y., Arimura N., Kawabata S., Kikuchi A., and Kaibuchi K. GSK-3beta regulates phosphorylation of CRMP-2 and neuronal polarity. Cell 120 1 (2005) 137-149
129. Yu G., Chen F., Levesque G., Nishimura M., Zhang D.M., Levesque L., Rogaeva E., Xu D., Liang Y., Duthie M., St George-Hyslop P.H., and Fraser P.E. The presenilin 1 protein is a component of a high molecular weight intracellular complex that contains beta-catenin. J. Biol. Chem. 273 26 (1998) 16470-16475
130. Zeng X., Huang H., Tamai K., Zhang X., Harada Y., Yokota C., Almeida K., Wang J., Doble B., Woodgett J., Wynshaw-Boris A., Hsieh J.C., and He X. Initiation of Wnt signaling: control of Wnt coreceptor Lrp6 phosphorylation/activation via frizzled, dishevelled and axin functions. Development 135 2 (2008) 367-375
131. Zeng X., Tamai K., Doble B., Li S., Huang H., Habas R., Okamura H., Woodgett J., and He X. A dual-kinase mechanism for Wnt co-receptor phosphorylation and activation. Nature 438 7069 (2005) 873-877
132. Zhang Q.G., Wang R., Khan M., Mahesh V., and Brann D.W. Role of Dickkopf-1, an antagonist of the Wnt/beta-catenin signaling pathway, in estrogen-induced neuroprotection and attenuation of tau phosphorylation. J. Neurosci. 28 34 (2008) 8430-8441
133. Zhang Z., Hartmann H., Do V.M., Abramowski D., Sturchler-Pierrat C., Staufenbiel M., Sommer B., van de Wetering M., Clevers H., Saftig P., De Strooper B., He X., and Yankner B.A. Destabilization of beta-catenin by mutations in presenilin-1 potentiates neuronal apoptosis. Nature 395 6703 (1998) 698-702